Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects

被引:51
作者
Nilsson, C. [1 ,2 ]
Aboud, S. [3 ]
Karlen, K. [1 ,2 ]
Hejdeman, B. [4 ,5 ]
Urassa, W. [3 ]
Biberfeld, G. [1 ,2 ]
机构
[1] Swedish Inst Infect Dis Control, Dept Immunol & Vaccinol, S-17182 Solna, Sweden
[2] Karolinska Inst, S-17182 Solna, Sweden
[3] Muhimbili Univ Hlth & Allied Sci, Dept Microbiol & Immunol, Dar Es Salaam, Tanzania
[4] Karolinska Hosp, S-10401 Stockholm, Sweden
[5] Karolinska Inst, Stockholm, Sweden
关键词
D O I
10.1128/CVI.00161-07
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Determination of antigen-specific T-cell responses is an important part of vaccine assessment. High levels of recovery, viability, and functionality of peripheral blood mononuclear cells (PBMCs) are essential for reliable assessment of cell-mediated immune responses. Here, we sought to find the cell preparation technique best suited for two clinical vaccine trial sites: Stockholm, Sweden, and Dar es Salaam, Tanzania. Standard Ficoll-Paque gradient centrifugation, BD Vacutainer cell preparation tube (CPT), and Greiner Bio-One LeucoSep tube techniques were tested. Cell yield and viability were recorded. Gamma interferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) testing was used to assess cell functionality. No differences in mean recovery or mean viability of fresh PBMCs were observed between Ficoll-Paque gradient centrifugation and CPT techniques as used in Stockholm. In Dar es Salaam, recovery of PBMCs isolated by use of the Ficoll-Paque gradient technique was higher than that seen with CPT ( 1.58 +/- 0.6 versus 1.34 +/- 0.4 million cells/ml of blood [P = 0.0469]), and the viability of PBMCs processed by Ficoll-Paque gradient was higher than that seen with CPT-purified cells (95.8% +/- 2.3% versus 92.6% +/- 4.8% [P = 0.0081]). Furthermore, LeucoSep cell separation gave higher levels of yield (1.10 +/- 0.3 versus 0.92 +/- 0.3 million cells/ml of blood [P = 0.0022]) and viability (95.7% +/- 2.0% versus 93.4% +/- 3.2% [P = 0.0012]) than Ficoll-Paque cell separation. The cells purified by the different techniques at the two sites performed equally well in IFN-gamma ELISPOT assays. Both techniques generated cell preparations with excellent yield, viability, and functionality in Stockholm. In Dar es Salaam, CPT did not perform as well as Ficoll-Paque separation. In a subsequent comparison, LeucoSep performed better than Ficoll-Paque separation. Our findings emphasize the need for on-site assessment of PBMC purification techniques for optimal evaluation of cell-mediated immune responses.
引用
收藏
页码:585 / 589
页数:5
相关论文
共 23 条
[1]   Field studies of cytotoxic T lymphocytes in malaria infections: Implications for malaria vaccine development [J].
Aidoo, M ;
Udhayakumar, V .
PARASITOLOGY TODAY, 2000, 16 (02) :50-56
[2]   Progress on new vaccine strategies against chronic viral infections [J].
Berzofsky, JA ;
Ahlers, JD ;
Janik, J ;
Morris, J ;
Oh, S ;
Terabe, M ;
Belyakov, IM .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (04) :450-462
[3]   HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells [J].
Betts, Michael R. ;
Nason, Martha C. ;
West, Sadie M. ;
De Rosa, Stephen C. ;
Migueles, Stephen A. ;
Abraham, Jonathan ;
Lederman, Michael M. ;
Benito, Jose M. ;
Goepfert, Paul A. ;
Connors, Mark ;
Roederer, Mario ;
Koup, Richard A. .
BLOOD, 2006, 107 (12) :4781-4789
[4]   Analysis of total human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell responses:: Relationship to viral load in untreated HIV infection [J].
Betts, MR ;
Ambrozak, DR ;
Douek, DC ;
Bonhoeffer, S ;
Brenchley, JM ;
Casazza, JP ;
Koup, RA ;
Picker, LJ .
JOURNAL OF VIROLOGY, 2001, 75 (24) :11983-11991
[5]  
BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
[6]   Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials [J].
Bull, Marta ;
Lee, Deborah ;
Stucky, Jason ;
Chiu, Ya-Lin ;
Rubin, Abbe ;
Horton, Helen ;
McElrath, M. Juliana .
JOURNAL OF IMMUNOLOGICAL METHODS, 2007, 322 (1-2) :57-69
[7]   Measurement of cytokine release at the single cell level using the ELISPOT assay [J].
Cox, JH ;
Ferrari, G ;
Janetzki, S .
METHODS, 2006, 38 (04) :274-282
[8]  
Cox JH, 2006, MANUAL OF MOLECULAR AND CLINICAL LABORATORY IMMUNOLOGY, 7TH EDITION, P301
[9]   A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays [J].
Currier, JR ;
Kuta, EG ;
Turk, E ;
Earhart, LB ;
Loomis-Price, L ;
Janetzki, S ;
Ferrari, G ;
Birx, DL ;
Cox, JH .
JOURNAL OF IMMUNOLOGICAL METHODS, 2002, 260 (1-2) :157-172
[10]   REVERSE ENZYME-LINKED IMMUNOSPOT ASSAY (RELISPOT) FOR THE DETECTION OF CELLS SECRETING IMMUNOREACTIVE SUBSTANCES [J].
CZERKINSKY, CC ;
TARKOWSKI, A ;
NILSSON, LA ;
OUCHTERLONY, O ;
NYGREN, H ;
GRETZER, C .
JOURNAL OF IMMUNOLOGICAL METHODS, 1984, 72 (02) :489-496